"Prof. N. Paulescu" National Institute of Diabetes, Nutrition and Metabolic Diseases-Bucharest, Romania.
Nutr J. 2013 Aug 14;12:119. doi: 10.1186/1475-2891-12-119.
In patients with chronic hepatitis C (CHC), obesity is involved in the pathogenesis of insulin resistance, fatty liver disease and progression of fibrosis. The objective of this study was to compare a normoglucidic low-calorie diet (NGLCD) with a low-fat diet (LFD) among participants with CHC. Aimed to measure the impact of dietary changes in reduction of insulin resistance, obesity but also in steatosis and fibrosis.
Randomized, controlled trial in three medical centers with assessments at baseline, 6 months and 12 months. Participants were patients over 35 years with chronic hepatitis C (n = 120) with BMI over 25 kg/m². We evaluated the effects of NGLCD vs. LFD in weight management and metabolic improvement. The primary endpoint was to measure the impact of dietary changes through nutritional intervention in reversibility of insulin resistance, obesity, steatosis, and fibrosis. We performed anthropometric measurements, fasting glucose profile, serum lipids, liver profile, blood count at baseline, 6 and 12 months. Steatosis was evaluated using ultrasonographic criteria. Liver fibrosis was non-invasively assessed.
After 6 and 12 months of intervention, both groups had a significant decrease in caloric consumption. At 6 months, weight loss was greater in the NGLCD group (-5.02 ± 3.43 kg vs. -4.1 ± 2.6 kg; p = 0.002) compared to the LFD group. At 1-year, however, weight loss was similar in both groups (-3.9 ± 3.3 kg vs. -3.1 ± 2.6 kg; p = 0.139). At 12 months, fasting plasma glucose, fasting plasma insulin, and HOMA-IR had significant improvements in both groups. With both diets aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transpeptidase (GGT) decreased with significant differences; also there were significant improvements in AST/ALT ratio, Forns fibrosis index. The two diets were associated with reduction of both the prevalence and the severity of steatosis (all p < 0.001). At 12 months, total cholesterol, HDL-cholesterol, triglycerides improved in both groups (all p < 0.05).
The present study establishes the benefits of low-calorie diet and low-fat diet in management of patients with hepatitis C regarding improvement of insulin resistance, steatosis and also fibrosis.Overweight or obese patients with CHC undergoing a lifestyle intervention (specific dietary intervention and physical activity) for 1-year had significant improvements in body weight, lipid and hepatic profile.
PNCI2-3343/41008/2007.
在慢性丙型肝炎(CHC)患者中,肥胖参与胰岛素抵抗、脂肪肝疾病和纤维化进展的发病机制。本研究的目的是比较 CHC 患者的低糖低脂饮食(LFD)和低糖正常热量饮食(NGLCD)。旨在测量饮食变化对胰岛素抵抗、肥胖、脂肪变性和纤维化减轻的影响。
在三个医学中心进行随机对照试验,在基线、6 个月和 12 个月进行评估。参与者为年龄超过 35 岁、BMI 超过 25kg/m²的慢性丙型肝炎患者(n=120)。我们评估了 NGLCD 与 LFD 在体重管理和代谢改善方面的效果。主要终点是通过营养干预测量饮食变化对胰岛素抵抗、肥胖、脂肪变性和纤维化逆转的影响。我们在基线、6 个月和 12 个月进行了人体测量学测量、空腹血糖谱、血清脂质、肝功能、血常规。使用超声标准评估脂肪变性。非侵入性评估肝纤维化。
干预 6 个月和 12 个月后,两组的热量摄入均显著下降。在 6 个月时,NGLCD 组的体重减轻幅度大于 LFD 组(-5.02±3.43kg 比-4.1±2.6kg;p=0.002)。然而,在 1 年时,两组的体重减轻相似(-3.9±3.3kg 比-3.1±2.6kg;p=0.139)。在 12 个月时,两组的空腹血浆葡萄糖、空腹血浆胰岛素和 HOMA-IR 均显著改善。两种饮食的天冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)、γ-谷氨酰转肽酶(GGT)均下降,差异有统计学意义;AST/ALT 比值、Forns 纤维化指数也有显著改善。两种饮食均可降低脂肪变性的发生率和严重程度(均 p<0.001)。在 12 个月时,两组的总胆固醇、高密度脂蛋白胆固醇和甘油三酯均有所改善(均 p<0.05)。
本研究确立了低热量饮食和低脂肪饮食在管理丙型肝炎患者胰岛素抵抗、脂肪变性和纤维化方面的益处。超重或肥胖的 CHC 患者接受为期 1 年的生活方式干预(特定的饮食干预和体育活动)可显著改善体重、血脂和肝功能。
PNCI2-3343/41008/2007。